| Literature DB >> 31597291 |
Elizabeth R Stirling1,2, Katherine L Cook3,4,5, David D Roberts6, David R Soto-Pantoja7,8,9,10.
Abstract
The goal of this study was to interrogate biochemical profiles manifested in mouse lung tissue originating from wild type (WT) and cd47 null mice with the aim of revealing the in vivo role of CD47 in the metabolic response to ionizing radiation, especially changes related to the known association of CD47 deficiency with increased tissue viability and survival. For this objective, we performed global metabolomic analysis in mouse lung tissue collected from (C57Bl/6 background) WT and cd47 null mice with and without exposure to 7.6 Gy whole body radiation. Principal component analysis and hierarchical clustering revealed a consistent separation between genotypes following radiation exposure. Random forest analysis also revealed a unique biochemical signature in WT and cd47 null mice following treatment. Our data show that cd47 null irradiated lung tissue activates a unique set of metabolic pathways that facilitate the handling of reactive oxygen species, lipid metabolism, nucleotide metabolism and nutrient metabolites which may be regulated by microbial processing. Given that cd47 has pleiotropic effects on responses to ionizing radiation, we not only propose this receptor as a therapeutic target but postulate that the biomarkers regulated in this study associated with radioprotection are potential mitigators of radiation-associated pathologies, including the onset of pulmonary disease.Entities:
Keywords: CD47; amino acid; fatty acid; ionizing radiation; lipid; radiation-induced lung injury; redox; thrombospondin-1; xenobiotics
Year: 2019 PMID: 31597291 PMCID: PMC6835245 DOI: 10.3390/metabo9100218
Source DB: PubMed Journal: Metabolites ISSN: 2218-1989
Figure 1WT and cd47 null mice demonstrate different biochemical signatures after exposure to ionizing radiation. WT and cd47 null mice were left untreated or were exposed to whole body irradiation (7.6 Gy). After 24 h, lungs were harvested and processed for metabolomic analysis. (A) Principal component analysis of lung tissues of WT and cd47 null mice with or without exposure to whole body irradiation. Random forest analysis of (B) WT irradiated or (C) cd47 null lung irradiated tissues. n = 7–8/group.
Figure 2Regulation of glutathione metabolism. (A) Reduced (GSH) and (B) oxidized (GSSG) glutathione were measured along with metabolite precursors (C) (S-methylglutathione) and (D) 5-oxoproline. Symbols denote outliers. (* p < 0.05, n = 7–8).
Levels and ratios of reduced and oxidized glutathione.
| Glutathione, Reduced (GSH) | Glutathione, Oxidized (GSSG) | GSH:GSSG | |||
|---|---|---|---|---|---|
| Treatment | Average SEM | Treatment | Average SEM | Treatment | Ratio |
| WT | 2.138 ± 0.6102 | WT | 1.007 ± 0.06007 | WT | 2.12 |
|
| 2.830 ± 1.666 |
| 0.9818 ± 0.05081 |
| 2.88 |
| WT + IR | 0.9412 ± 0.1702 | WT + IR | 1.009 ± 0.03887 | WT + IR | 0.93 |
| 3.025 ± 2.002 | 0.9909 ± 0.01972 | 3.05 | |||
Figure 3Regulation of lipid metabolism in lungs as a response to ionizing radiation. Lipid metabolites (A) Palmitoleate, (B) Myriostoleate, (C) Carnitine, (D) Palmitocarnitine, (E) Stearoylcarninitne and (F) BHBA of lung tissues were measured 24 h after exposure to whole body irradiation. Symbols denote outliers. (* p < 0.05, n = 7–8).
Figure 4Regulation of cell membrane lipid metabolites after exposure to ionizing radiation. (A) Choline, (B) Choline phosphate, (C) Cytidine 5′-disphosphocholine, (D) Glycerol 3-phosphate, (E) Glycerophosphorycholine, (F) 1-stearolglycerophosphocoline, (G) Sphingannine, (H) Sphingosine, (I) Stearoyl sphiongomyelin and (J) N-palmitoyl-D-erythro-sphingosines were measured in lungs of mice exposed to ionizing radiation. Symbols denote outliers. (* p < 0.05, n = 7–8).
Lysolipid metabolites fold change.
| Lysolipid Metabolites | ANOVA Contrasts | |||
|---|---|---|---|---|
| Fold of Change | ||||
| IR | CD47-/- | |||
| WT | CD47-/- | CTRL | IR | |
| 1-myristoylglycerophosphocholine (14:0) | 4.01 | 1.35 | 1.23 | 0.41 |
| 2-myristoylglycerophosphocholine | 3.99 | 1.09 | 1.29 | 0.35 |
| 1-palmitoylglycerophosphocholine (16:0) | 3.68 | 1.08 | 1.38 | 0.41 |
| 2-palmitoylglycerophosphocholine | 5.29 | 1.12 | 1.57 | 0.33 |
| 1-palmitoleoylglycerophosphocholine (16:1) | 3.86 | 1.18 | 1.21 | 0.37 |
| 2-palmitoleoylglycerophosphocholine | 4.29 | 1.17 | 1.30 | 0.35 |
| 1-stearoylglycerophosphocholine (18:0) | 5.35 | 1.21 | 1.85 | 0.42 |
| 2-stearoylglycerophosphocholine | 4.65 | 1.61 | 1.25 | 0.43 |
| 1-oleoylglycerophosphocholine (18:1) | 4.08 | 1.02 | 1.52 | 0.38 |
| 2-oleoylglycerophosphocholine | 4.66 | 1.10 | 1.31 | 0.31 |
| 1-linoleoylglycerophosphocholine (18:2n6) | 4.19 | 1.13 | 1.43 | 0.39 |
| 2-linoleoylglycerophosphocholine | 4.05 | 1.11 | 1.39 | 0.38 |
| 1-eicosatrienoylglycerophosphocholine (20:3) | 2.28 | 0.94 | 1.10 | 0.45 |
| 1-arachidonoylglycerophosphocholine (20:4n6) | 6.11 | 0.93 | 1.59 | 0.24 |
| 2-arachidonoylglycerophosphocholine | 4.22 | 1.40 | 1.21 | 0.40 |
| 1-docosapentaenoylglycerophosphocholine (22:5n3) | 3.31 | 1.57 | 0.84 | 0.40 |
| 2-docosapentaenoylglycerophosphocholine (22:5n3) | 4.94 | 1.27 | 1.28 | 0.33 |
| 1-docosahexaenoylglycerophosphocholine (22:6n3) | 3.96 | 1.28 | 1.29 | 0.42 |
| 2-docosahexaenoylglycerophosphocholine | 5.23 | 1.34 | 1.45 | 0.37 |
| 1-palmitoylplasmenylethanolamine | 1.57 | 1.21 | 0.84 | 0.64 |
| 1-stearoylplasmenylethanolamine | 0.94 | 1.29 | 0.80 | 1.10 |
| 1-oleoylplasmenylethanolamine | 1.60 | 1.16 | 0.95 | 0.69 |
| 1-palmitoylglycerophosphoethanolamine | 1.34 | 1.14 | 0.82 | 0.70 |
| 2-palmitoylglycerophosphoethanolamine | 4.49 | 1.05 | 1.63 | 0.38 |
| 1-stearoylglycerophosphoethanolamine | 1.80 | 1.15 | 0.97 | 0.62 |
| 1-oleoylglycerophosphoethanolamine | 1.33 | 0.93 | 0.97 | 0.68 |
| 2-oleoylglycerophosphoethanolamine | 1.40 | 1.08 | 1.01 | 0.78 |
| 1-linoleoylglycerophosphoethanolamine | 1.22 | 0.91 | 1.05 | 0.78 |
| 2-linoleoylglycerophosphoethanolamine | 3.05 | 1.01 | 1.39 | 0.46 |
| 1-arachidonoylglycerophosphoethanolamine | 1.22 | 1.04 | 1.07 | 0.91 |
| 2-arachidonoylglycerophosphoethanolamine | 3.22 | 1.09 | 1.33 | 0.45 |
| 2-docosapentaenoylglycerophosphoethanolamine | 7.07 | 1.09 | 1.79 | 0.28 |
| 2-docosahexaenoylglycerophosphoethanolamine* | 4.08 | 1.11 | 1.60 | 0.43 |
| 1-eicosatrienoylglycerophosphoethanolamine | 1.35 | 1.04 | 0.97 | 0.75 |
| 2-eicosapentaenoylglycerophosphoethanolamine | 4.87 | 1.04 | 1.50 | 0.32 |
| 1-docosahexaenoylglycerophosphoethanolamine | 1.29 | 1.18 | 1.02 | 0.93 |
| 1-eicosenoylglycerophosphoethanolamine (20:1n9) | 1.42 | 0.97 | 1.09 | 0.74 |
| 1-palmitoylglycerophosphoinositol | 1.05 | 0.98 | 0.92 | 0.87 |
| 1-stearoylglycerophosphoinositol | 1.20 | 1.15 | 0.88 | 0.84 |
| 2-stearoylglycerophosphoinositol | 1.55 | 1.04 | 1.11 | 0.75 |
| 1-oleoylglycerophosphoinositol | 0.94 | 0.82 | 1.03 | 0.89 |
| 1-arachidonoylglycerophosphoinositol | 0.96 | 0.96 | 0.87 | 0.86 |
| 2-arachidonoylglycerophosphoinositol | 1.04 | 1.02 | 0.90 | 0.88 |
| 1-stearoylglycerophosphoserine | 1.16 | 1.14 | 0.83 | 0.82 |
| 1-oleoylglycerophosphoserine | 1.10 | 0.93 | 0.90 | 0.76 |
| 2-oleoylglycerophosphoserine | 1.18 | 1.24 | 0.70 | 0.74 |
| 1-palmitoylglycerophosphoglycerol | 1.08 | 1.26 | 0.70 | 0.82 |
| 2-palmitoylglycerophosphoglycerol | 1.12 | 1.17 | 0.91 | 0.95 |
| 1-stearoylglycerophosphoglycerol | 1.15 | 1.48 | 0.66 | 0.85 |
| 2-stearoylglycerophosphoglycerol | 1.07 | 1.56 | 0.64 | 0.93 |
| 1-oleoylglycerophosphoglycerol | 1.14 | 1.14 | 0.83 | 0.83 |
| 2-oleoylglycerophosphoglycerol | 1.38 | 1.49 | 0.70 | 0.76 |
Red = p ≤ 0.05, fold change ≥ 1.00; Green = p ≤ 0.05, fold change < 1.00.
Regulation of nucleotide metabolism intermediates.
| IR | CD47-/- | ||||
|---|---|---|---|---|---|
| Metabolite | WT | CD47 -/- | CTRL | IR | |
| Purine Metabolism, (Hypo)Xanthine/Inosine containing | inosine 5′-monophosphate (IMP) | 0.11 | 0.08 | 2.80 | 2.09 |
| inosine | 0.72 | 0.84 | 1.00 | 1.17 | |
| hypoxanthine | 0.99 | 1.07 | 0.91 | 0.98 | |
| xanthine | 1.07 | 1.12 | 0.92 | 0.96 | |
| xanthosine | 1.20 | 1.12 | 1.07 | 1.00 | |
| urate | 1.11 | 1.26 | 0.86 | 0.97 | |
| allantoin | 0.82 | 0.79 | 1.08 | 1.05 | |
| Purine Metabolism, | adenosine 5′-diphosphate (ADP) | 1.05 | 0.89 | 1.20 | 1.02 |
| adenosine 5′-monophosphate (AMP) | 0.69 | 0.46 | 1.63 | 1.09 | |
| adenosine 3′-monophosphate (3′-AMP) | 0.45 | 0.50 | 1.00 | 1.12 | |
| adenosine 2′-monophosphate (2′-AMP) | 1.19 | 1.46 | 0.72 | 0.89 | |
| adenosine 3′,5′-cyclic monophosphate (cAMP) | 0.91 | 1.10 | 0.93 | 1.13 | |
| adenosine 3′,5′-diphosphate | 0.99 | 1.24 | 0.88 | 1.11 | |
| adenosine | 1.10 | 0.95 | 1.25 | 1.07 | |
| adenine | 0.89 | 1.13 | 0.75 | 0.95 | |
| N1-methyladenosine | 1.02 | 0.96 | 1.04 | 0.98 | |
| Purine Metabolism, | guanosine 5′- monophosphate (5′-GMP) | 0.32 | 0.15 | 3.01 | 1.37 |
| guanosine 3′-monophosphate (3′-GMP) | 0.71 | 0.73 | 0.97 | 1.00 | |
| guanosine | 0.33 | 0.58 | 1.13 | 1.99 | |
| Pyrimidine Metabolism, | uridine monophosphate (5′ or 3′) | 0.60 | 0.51 | 1.80 | 1.52 |
| uridine | 1.12 | 1.15 | 1.03 | 1.05 | |
| uracil | 1.10 | 1.29 | 0.80 | 0.94 | |
| pseudouridine | 0.93 | 0.83 | 1.14 | 1.01 | |
| 3-ureidopropionate | 1.18 | 1.08 | 1.03 | 0.94 | |
| beta-alanine | 0.91 | 0.90 | 1.13 | 1.12 | |
| Pyrimidine Metabolism, | cytidine 5′-monophosphate (5′-CMP) | 0.88 | 0.99 | 0.84 | 0.94 |
| cytidine-3′-monophosphate (3′-CMP) | 0.18 | 0.22 | 0.94 | 1.15 | |
| cytidine | 1.08 | 1.07 | 0.90 | 0.89 | |
| 2′-deoxycytidine | 2.11 | 1.35 | 1.11 | 0.71 | |
| Pyrimidine Metabolism, | thymidine | 1.04 | 1.53 | 1.98 | 2.92 |
| thymine | 1.37 | 1.48 | 1.52 | 1.64 | |
| Purine and Pyrimidine Metabolism | methylphosphate | 0.87 | 1.15 | 0.76 | 0.99 |
Red = p ≤ 0.05, fold change ≥ 1.00; Green = p ≤ 0.05, fold change < 1.00.
Figure 5Regulation of nucleotide metabolism. Purines metabolism metabolites (A) Guanosine 5′-monophosphate (B) Guanosine and Pyrimidine metabolism metabolites (C) Thymidine, (D) Thymine was measured in lungs of mice exposed to IR. (E) Pyrophosphate metabolite levels were measured as a surrogate of nucleotide metabolism activity. Symbols denote outliers. (* p < 0.05, n = 7–8).
Figure 6Regulation of nutrient and xenobiotic metabolite processing after exposure to ionizing radiation. (A) alpha-tocopherol, (B) Erythritol, (C) Hippurate, (D) Catechol sulfate and (E) Ergothioneine metabolites were measured in lungs of mice with or without whole body irradiation. Symbols denote outliers. (* p < 0.05, n = 7–8).